secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0000950170-25-058966
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo enters ATM equity facility up to $2.96M; reports preliminary Q1 cash of $2.1M
--------------------------------------------------------------------------------

- Entered ATM sales agreement with Roth Capital to sell up to $2,959,952 in common stock; Roth receives 3.0% commission.
- Preliminary cash and equivalents as of March 31, 2025: $2.1M (unaudited, subject to change).
- Subsequent registered direct offerings on April 4 and April 22 raised approx. $1.9M and $1.8M respectively.
- Company has not finalized Q1 2025 financial results; independent auditor has not reviewed preliminary data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025058966/0000950170-25-058966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025058966/apvo-20250428.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-058966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer